Effekten af statiner på eksacerbationer og dødelighed ved KOL

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Effekten af statiner på eksacerbationer og dødelighed ved KOL. / Damkjær, Mathias; Håkansson, Kjell E J; Ulrik, Charlotte S; Godtfredsen, Nina S.

In: Ugeskrift for Laeger, Vol. 182, No. 23, V10190592, 2020.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Damkjær, M, Håkansson, KEJ, Ulrik, CS & Godtfredsen, NS 2020, 'Effekten af statiner på eksacerbationer og dødelighed ved KOL', Ugeskrift for Laeger, vol. 182, no. 23, V10190592. <https://ugeskriftet.dk/files/scientific_article_files/2020-06/v10190592_web.pdf>

APA

Damkjær, M., Håkansson, K. E. J., Ulrik, C. S., & Godtfredsen, N. S. (2020). Effekten af statiner på eksacerbationer og dødelighed ved KOL. Ugeskrift for Laeger, 182(23), [V10190592]. https://ugeskriftet.dk/files/scientific_article_files/2020-06/v10190592_web.pdf

Vancouver

Damkjær M, Håkansson KEJ, Ulrik CS, Godtfredsen NS. Effekten af statiner på eksacerbationer og dødelighed ved KOL. Ugeskrift for Laeger. 2020;182(23). V10190592.

Author

Damkjær, Mathias ; Håkansson, Kjell E J ; Ulrik, Charlotte S ; Godtfredsen, Nina S. / Effekten af statiner på eksacerbationer og dødelighed ved KOL. In: Ugeskrift for Laeger. 2020 ; Vol. 182, No. 23.

Bibtex

@article{537a724365914d43a43b8761bd68cf91,
title = "Effekten af statiner p{\aa} eksacerbationer og d{\o}delighed ved KOL",
abstract = "The role of statins on the disease course of COPD is controversial. Observational studies have shown a reduction in mortality and exacerbations, but results of randomised clinical trials (RCTs) of statin treatment and its effect on adverse outcomes are conflicting. Recent meta-analyses suggest the need for further RCTs including COPD patients both with and without concurrent cardiovascular disease (CVD). As there are no known detrimental effects of statins in COPD patients, we conclude in this review, that statins should be prescribed more frequently in these patients due to the common co-morbidity with CVD.",
author = "Mathias Damkj{\ae}r and H{\aa}kansson, {Kjell E J} and Ulrik, {Charlotte S} and Godtfredsen, {Nina S}",
year = "2020",
language = "Dansk",
volume = "182",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "23",

}

RIS

TY - JOUR

T1 - Effekten af statiner på eksacerbationer og dødelighed ved KOL

AU - Damkjær, Mathias

AU - Håkansson, Kjell E J

AU - Ulrik, Charlotte S

AU - Godtfredsen, Nina S

PY - 2020

Y1 - 2020

N2 - The role of statins on the disease course of COPD is controversial. Observational studies have shown a reduction in mortality and exacerbations, but results of randomised clinical trials (RCTs) of statin treatment and its effect on adverse outcomes are conflicting. Recent meta-analyses suggest the need for further RCTs including COPD patients both with and without concurrent cardiovascular disease (CVD). As there are no known detrimental effects of statins in COPD patients, we conclude in this review, that statins should be prescribed more frequently in these patients due to the common co-morbidity with CVD.

AB - The role of statins on the disease course of COPD is controversial. Observational studies have shown a reduction in mortality and exacerbations, but results of randomised clinical trials (RCTs) of statin treatment and its effect on adverse outcomes are conflicting. Recent meta-analyses suggest the need for further RCTs including COPD patients both with and without concurrent cardiovascular disease (CVD). As there are no known detrimental effects of statins in COPD patients, we conclude in this review, that statins should be prescribed more frequently in these patients due to the common co-morbidity with CVD.

M3 - Tidsskriftartikel

C2 - 32515342

VL - 182

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 23

M1 - V10190592

ER -

ID: 262818243